全文获取类型
收费全文 | 972篇 |
免费 | 76篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 58篇 |
妇产科学 | 8篇 |
基础医学 | 85篇 |
口腔科学 | 30篇 |
临床医学 | 191篇 |
内科学 | 198篇 |
皮肤病学 | 12篇 |
神经病学 | 33篇 |
特种医学 | 246篇 |
外科学 | 50篇 |
综合类 | 21篇 |
预防医学 | 41篇 |
眼科学 | 7篇 |
药学 | 34篇 |
中国医学 | 5篇 |
肿瘤学 | 33篇 |
出版年
2024年 | 2篇 |
2023年 | 8篇 |
2022年 | 2篇 |
2021年 | 11篇 |
2020年 | 6篇 |
2019年 | 6篇 |
2018年 | 23篇 |
2017年 | 11篇 |
2016年 | 18篇 |
2015年 | 21篇 |
2014年 | 26篇 |
2013年 | 26篇 |
2012年 | 19篇 |
2011年 | 19篇 |
2010年 | 36篇 |
2009年 | 56篇 |
2008年 | 28篇 |
2007年 | 17篇 |
2006年 | 15篇 |
2005年 | 8篇 |
2004年 | 7篇 |
2003年 | 14篇 |
2002年 | 14篇 |
2001年 | 15篇 |
2000年 | 11篇 |
1999年 | 13篇 |
1998年 | 52篇 |
1997年 | 55篇 |
1996年 | 65篇 |
1995年 | 49篇 |
1994年 | 43篇 |
1993年 | 47篇 |
1992年 | 17篇 |
1991年 | 11篇 |
1990年 | 16篇 |
1989年 | 36篇 |
1988年 | 30篇 |
1987年 | 33篇 |
1986年 | 33篇 |
1985年 | 23篇 |
1984年 | 16篇 |
1983年 | 9篇 |
1982年 | 22篇 |
1981年 | 14篇 |
1980年 | 8篇 |
1979年 | 2篇 |
1978年 | 5篇 |
1977年 | 12篇 |
1976年 | 11篇 |
1975年 | 13篇 |
排序方式: 共有1055条查询结果,搜索用时 46 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
3.
4.
5.
6.
7.
8.
9.
10.
Gerald L DeNardo Arutselvan Natarajan Saphon Hok Julie Perkins Monique Cosman Sally J DeNardo Felice C Lightstone Gary R Mirick Laird A Miers Rodney L Balhorn 《Journal of nuclear medicine》2007,48(8):1338-1347
Despite their large size, antibodies (Abs) are suitable carriers to deliver systemic radiotherapy, often molecular image-based, for lymphoma and leukemia. Lym-1 Ab has proven to be an effective radioisotope carrier, even in small amounts, for targeting human leukocyte antigen DR (HLA-DR), a surface membrane protein overexpressed on B-cell lymphoma. Pairs of molecules (referred to as ligands), shown by computational and experimental methods to bind to each of 2 sites within the Lym-1 epitopic region, have been linked to generate small (<2 kDa) molecules (referred to as selective high-affinity ligands [SHALs]) to mimic the targeting properties of Lym-1 Ab. METHODS: A lysine-polyethylene glycol (PEG) backbone was used to synthetically link 2 of the following ligands: deoxycholate, 5-leuenkephalin, triiodothyronine, thyronine, dabsyl-L-valine, and N-benzoyl-L-arginyl-4-amino-benzoic acid to generate a series of 13 bidentate SHALs with a biotin or 1,4,7,10-tetraazacyclododecane-N,N',N',N'-tetraacetic acid (DOTA) chelate attached to the linker. These SHALs have been assessed for their selectivity in binding to HLA-DR10-expressing cells and for their pharmacokinetics and tissue biodistribution in mice. Biotinylated versions of these SHALs discriminated cell lines positive for HLA-DR10 expression with near-nanomolar affinity. The DOTA versions of 4 SHALs were labeled with (111)In for pharmacokinetic studies in mice with HLA-DR10-expressing malignant Raji xenografts. RESULTS: The bidentate, biotinylated, and DOTA-SHALs were synthesized in high-purity, multimilligram amounts. Mean radiochemical and product yields and purities were 90%, 75%, and 90% at mean specific activities of 3.9 MBq/microg (105 microCi/microg) for the (111)In-labeled SHALs. As expected, rapid blood clearance and tumor targeting were observed. The pharmacokinetics of the SHALs was influenced by the component ligands. Biliary clearance, kidney localization, and serum receptor binding contributed to less favorable tumor targeting. CONCLUSION: A series of SHALs was readily synthesized in multimilligram amounts and showed the expected selective binding in vitro. Better selection of the SHAL components should provide second-generation SHALs with improved properties to fulfill the substantial potential of these novel molecular carriers for targeting. 相似文献